Impact of Rapid Molecular Multiplex Gastrointestinal Pathogen Testing in Management of Children during a Shigella Outbreak
- PMID: 36853032
- PMCID: PMC10035298
- DOI: 10.1128/jcm.01652-22
Impact of Rapid Molecular Multiplex Gastrointestinal Pathogen Testing in Management of Children during a Shigella Outbreak
Abstract
Fecal culture for isolation and identification of Shigella may take days. The BioFire FilmArray Gastrointestinal (GI) panel (bioMérieux, France) is a PCR-based assay that detects enteric pathogens including Shigella/enteroinvasive Escherichia coli (EIEC) in about an hour. The aim of this study was to evaluate the impact of GI panel detection of Shigella in a pediatric emergency department (ED) during an outbreak. Stool samples from children with acute gastroenteritis were tested by the GI panel. Test results were either withheld in preintervention (PRE) or reported to clinicians/families in the postintervention (POST) period. The impact of the GI panel testing on patient management and outcomes was measured. Shigella/EIEC was identified by the GI panel in the PRE (n = 30) and POST (n = 21) phase. The GI panel detected more Shigella infections than did culture; six of 31 (19.4%) Shigella GI panel-positive patients who also had stool cultures were missed by culture. Azithromycin therapy was prescribed for 20% of subjects in the PRE phase and 71.4% of subjects in the POST phase (P < 0.001). Time from the clinical encounter until starting azithromycin therapy was shorter in the POST phase (n = 9), 8.25 h (range, 6.37 to 52.37 h), than in the PRE phase (n = 1), 72 h. Six subjects in the PRE phase visited additional providers compared with one in the POST phase. Prompt diagnosis of shigellosis with the GI panel may provide the opportunity for prompt antimicrobial therapy and avoid additional visits to providers due to early definitive diagnosis. Prompt diagnosis of Shigella at an ED visit may optimize patient management and reduce transmission.
Keywords: BioFire GI panel; GI panel; IMPACT study; Shigella detection; outbreak management; shigellosis.
Conflict of interest statement
The authors declare a conflict of interest. The study was sponsored by Biofire Diagnostics.
Figures
References
-
- GBD 2016 Diarrhoeal Disease Collaborators. 2018. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 18:1211–1228. doi:10.1016/S1473-3099(18)30362-1. - DOI - PMC - PubMed
-
- Huang JY, Henao OL, Griffin PM, Vugia DJ, Cronquist AB, Hurd S, Tobin-D’Angelo M, Ryan P, Smith K, Lathrop S, Zansky S, Cieslak PR, Dunn J, Holt KG, Wolpert BJ, Patrick ME. 2016. Infection with pathogens transmitted commonly through food and the effect of increasing use of culture-independent diagnostic tests on surveillance–Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 2012–2015. MMWR Morb Mortal Wkly Rep 65:368–371. doi:10.15585/mmwr.mm6514a2. - DOI - PubMed
-
- Khalil I, Lorkowski S. 2017. The global burden of Shigella and enterotoxigenic E. coli: results from the Global Burden of Disease Study 2016. Open Forum Infect Dis 4:S365. doi:10.1093/ofid/ofx163.892. - DOI
-
- Iwamoto M, Huang J, Cronquist A, Medus C, Hurd S, Zansky S, Dunn J, Woron A, Oosmanally N, Griffin P, Besser J, Henao O, Centers for Disease Control and Prevention . 2015. Bacterial enteric infections detected by culture-independent diagnostic tests–FoodNet, United States, 2012–2014. MMWR Morb Mortal Wkly Rep 64:252–257. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
